‘We’re On The Edge Of Knowledge,’ Says Dewpoint CEO

Biomolecular condensates were first observed over 100 years ago, but their function – and the role they might play in a broad range of diseases – is only now being rigorously explored by drug developers. New technological development is helping scientists recreate condensates in laboratory conditions, providing insight into fundamental cellular processes. Amir Nashat, CEO of Dewpoint Therapeutics, told In Vivo that the company, following a recent $77m series B round, now has the resources to get to proof of concept for drugs targeting biomolecular condensates.

Bubbles
• Source: Shutterstock

Dewpoint Therapeutics, with headquarters in Cambridge, Massachusetts and Dresden, Germany, believes understanding and targeting biomolecular condensates – droplets without membranes that form in the cell through a process called phase separation – represents the next “tectonic shift” in drug discovery. With 16 years at investment firm Polaris Partners and multiple start-up CEO roles under his belt, CEO Amir Nashat, who received an Sc.D from Massachusetts Institute of Technology (MIT) in chemical engineering and a biology minor under the tutelage of MIT’s Bob Langer, said he’s never seen anything “so architecturally relevant … to everything in biology.”

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Innovation

Merck KGaA’s Digital Biomarker Strategy For Commercial Gains In Neurology

 
• By 

The integration of digital health tools into clinical research and patient care is gaining momentum, and Merck KGaA is not letting the grass grow under its feet. With an approach to digital biomarkers, the company is seeking to redefine how neurological diseases are monitored and managed.

Podcast: iOnctura’s Mission To Treat Rare Cancers With Precision Therapies

 
• By 

In Vivo spoke with Catherine Pickering, the CEO and founder of iOnctura, a UK-based clinical stage biotech company developing therapies for uveal melanoma and other hard-to-treat cancers by disrupting the tumor-stroma-immune interface.

Building The Worm Atlas For I&I Breakthroughs

 
• By 

The next big thing in auto-immune therapies: worms. Or so a young California biotech believes. Holoclara is pioneering a new class of medicines derived from intestinal worms to revolutionize the treatment of autoimmune diseases, allergies, and more.

BioBytes: AI-Related Deals In Q1 2025

 
• By 

AI-related deal activitiy in the first quarter of 2025 was punctuated by a last-minute $600m raise for Isomorphic Labs.

More from In Vivo

Building The Worm Atlas For I&I Breakthroughs

 
• By 

The next big thing in auto-immune therapies: worms. Or so a young California biotech believes. Holoclara is pioneering a new class of medicines derived from intestinal worms to revolutionize the treatment of autoimmune diseases, allergies, and more.

Reforming The Rx Rulers: A New Script For PBMs

 
• By 

As PBMs shift to value-based contracts, federal and state efforts seek to reduce drug costs, increase transparency and tackle anticompetitive practices.

Podcast: OSE Immunotherapeutics’ CEO On Ulcerative Colitis Asset

 
• By 

Nicolas Poirier, CEO of French biotech OSE Immunotherapeutics, spoke with In Vivo about the company's anti-IL-7R antibody, lusvertikimab, on the heels of impressive ulcerative colitis data presented at the 2025 European Crohn's and Colitis Organization meeting.